Recent breakthroughs in breast cancer treatment for both ER+ and TNBC subtypes have emerged from multidimensional synergistic strategies involving temporal regulation, immune microenvironment remodeling, and metabolic intervention (57). This evidence concerns the gene PIEZO1 and breast carcinoma.